Paper Review Records
全部论文审稿周期
24 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接
49
天
Fluzoparib combined with docetaxel followed by epirubicin and cyclophosphamide as neoadjuvant therapy in HRD-positive and/or gBRCA-mutated HR+/HER2- early breast cancer: a single-arm phase II study
作者
Zhe Wang; Liu Yang; Pu Du; Ge Zhao; Lan Hou; Yuan Qin; Huan Zhang; Zelin Tian; Yike Li; Mingkun Zhang; Juliang Zhang展开收起
作者单位
1. Department of Thyroid, Breast and Vascular Surgery, Xijing Hospital, The Fourth Military Medical University, Xi’an, China; 2. School of Medicine, Northwest University, Xi’an, China展开收起
184
天
Association between screen-detected health-related social needs and nonadherence to endocrine therapy in patients with nonmetastatic breast cancer: an observational study
作者
Nadia Liyanage-Don; David DeStephano; Claire Sathe; Shing Lee; Melissa Beauchemin; Melissa Accordino; Dawn Hershman; Ian M. Kronish展开收起
作者单位
1. Department of Medicine, Columbia University Irving Medical Center, New York, USA; 2. Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, USA; 3. Department of Biostatistics, Columbia University Mailman School of Public Health, New York, USA展开收起
66
天
The landscape of cell surface target expression in treatment resistant early-stage breast cancer
作者
Per Karlsson; Marina N. Sharifi; Erik Holmberg; Hamza Bakhtiar; Emma Niméus; Fredrika Killander; Martin Sjöström; Shuang G. Zhao展开收起
作者单位
1. Department of Oncology, Institute of Clinical Sciences, University of Gothenburg, Gothenburg, Sweden; 2. Department of Medicine, University of Wisconsin, Madison, USA; 3. Department of Radiation Medicine, University of Wisconsin, Madison, USA; 4. Institute of Clinical Sciences, Lund University, Lund, Sweden; 5. Department of Surgery, Skåne University Hospital, Malmö, Sweden; 6. Department of Haematology, Oncology, Radiations Physics, Skåne University Hospital, Lund, Sweden; 7. Department of Urology, University of California, San Francisco, USA; 8. University of Texas MD Anderson Cancer Center, Houston, USA展开收起
229
天
Chemoendocrine therapy versus tamoxifen with ovarian function suppression in women with node-positive breast cancer
作者
Yung-Huyn Hwang; Sae Byul Lee; Jisun Kim; Il Yong Chung; BeomSeok Ko; Hee Jeong Kim; Jong Won Lee; Byung Ho Son; Tae-Kyung Robyn Yoo展开收起
作者单位
1. Division of Breast Surgery, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea, Republic of展开收起
105
天
Male breast cancer: clinicopathological features and prevalence of germline pathogenic variants
作者
P. V. B. D. Cerqueira; F. A. B. Campos; S. M. Caputo; E. Rouleau; H. K. Mantovani; L. R. da Silva; A. L. Cicilini; S. M. Sanches; F. Makdissi; A. A. B. A. da Costa; M. De Brot; C. Osório; V. Castro Vasconcelos; V. Cordeiro de Lima; J. C. Casali da rocha; D. Carraro; G. Torrezan; E. Santana dos Santos展开收起
作者单位
1. A.C. Camargo Cancer Center, São Paulo, Brazil; 2. Department of Oncology, Instituto De Assistência Médica Ao Servidor Público Estadual, São Paulo, Brasil; 3. Department of Oncology, Instituto de Assistência Médica ao Servidor Público Estadual (IAMSPE), São Paulo, Brazil; 4. Department of Genetics, Institut Curie, Paris Sciences Lettre University, Paris, France; 5. Department of Genetics, Gustave Roussy, Paris, France; 6. UNICAMP - Universidade Estadual de Campinas, São Paulo, Brasil展开收起
11
天
Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice
作者
Claire E. Smith; Avina Rami; Tianyu Li; Nabihah Tayob; Pooja Patel; Harold J. Burstein; Sandra McAllister; Rachel Abelman; Rachel A. Freedman展开收起
作者单位
1. Medical Oncology, Dana-Farber Cancer Institute, Boston, USA; 2. Department of Medicine, Harvard Medical School, Boston, USA; 3. Internal Medicine, Brigham and Women’s Hospital, Boston, USA; 4. Data Sciences, Dana-Farber Cancer Institute, Boston, USA; 5. Hematology Division, Brigham and Women’s Hospital, Boston, USA; 6. Mass General Brigham Cancer Institute, Boston, USA展开收起
FAQ
BREAST CANCER RESEARCH AND TREATMENT审稿要多久?
截至2026-11-19,CrushSCI 收录了 BREAST CANCER RESEARCH AND TREATMENT 的 24 篇完整审稿记录。最快一篇从收稿到录用用了 11 天(Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice,2026-10-02 收稿,2026-10-13 录用),最慢一篇用了 229 天;平均 114.4 天,中位数 108.5 天。
Expert Matching · Case Demo
把投稿要求,转成可验证的期刊方案
说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。
